lifestyle.californiaconsumerbanking.com

Author: Insilico Medicine

Insilico Medicine Announces Global R&D Collaboration with Lilly

May 4, 2026
Insilico Medicine and Tenacia Biotechnology Expand AI-Driven CNS Collaboration with Deal Value Up to US$94.75 Million

May 3, 2026
Insilico Medicine and ASKA Pharmaceutical Expand Partnership to Discover Novel Targets for Women’s Health

May 3, 2026
Insilico Medicine Launches PandaClaw: Empowering Biologists with Agentic AI for Therapeutic Discovery

May 3, 2026
Insilico Medicine to Announce 2025 Financial Results on March 30, 2026

May 2, 2026
Insilico and TaiGen Achieve Milestone in Collaboration: Out-Licensed CKD Anemia Candidate ISM4808 Completes first human enrollment and dosing in Phase I clinical trial

April 30, 2026
Insilico Medicine and Liquid AI Announce Strategic Partnership Delivering Lightweight Scientific Foundation Models for Drug Discovery

April 29, 2026
AI-Powered R&D Acceleration: Insilico Medicine and CMS announce multiple collaborations in central nervous system and autoimmune diseases

March 9, 2026
Insilico Medicine Appoints Halle Zhang, PhD (Med), as Vice President, Clinical Development – Oncology

March 9, 2026
Insilico Medicine Nominates ISM5059, the Peripheral-restricted NLRP3 Inhibitor as Preclinical Candidate, for the Treatment of Multiple Inflammatory and Metabolism Indications

March 9, 2026